Clinical Trial Update: Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of a novel antibody for esophageal metaplasia was terminated; reversibility of the condition was observed with a proton pump inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Metaplasia

Drugs mentioned

• Antibody therapy (undisclosed)
• Proton Pump Inhibitor (unspecified) (proton pump inhibitor)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Esophageal Metaplasia | Phase 3 | Status: TERMINATED